Abstract: The present invention relates to ampakines, including low impact ampakines, and pharmaceutical compositions and methods employing ampakines for treating central nervous system (CNS) disorders, including Spinal Cord Injuries. Novel compositions and methods are provided employing SCI recovery ampakines to treat attention deficit hyperactivity disorder (SCI) and related cognitive, behavioral and psychiatric conditions.

Abstract: Methods and compositions are provided for formulating and administering bicifadine and related compounds to treat or prevent functional impairment and disabilities associated with acute pain, chronic pain, and neuropathic disorders.

Abstract: Methods and compositions are provided for formulating and administering bicifadine and related compounds to treat or prevent functional impairment and disabilities associated with acute pain, chronic pain, and neuropathic disorders.

Abstract: Methods and compositions are provided for formulating and administering bicifadine and related compounds to treat or prevent functional impairment and disabilities associated with acute pain, chronic pain, and neuropathic disorders.

Abstract: The present invention provides novel compositions and methods for the controlling appetite and weight and/or treating obesity using a (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or related compound. The invention also provides novel compositions and methods for treating or preventing disorders related to or complicated by excessive body weight or obesity, including coronary heart disease, osteoarthritis, osteoporosis, dislipidemias, gout, atherosclerosis, joint pain, sexual and fertility problems, respiratory problems, gall bladder disease, skin conditions, hypertension, diabetes, stroke, pulmonary embolism, sleep apnea, idiopathic intracranial hypertension, lower extremity venous stasis disease, gastro-esophageal reflux, urinary stress incontinence, metabolic syndrome, insulin resistance and cancer. The methods and compositions of the invention may employ a (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.

Abstract: The present invention relates to (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable salts thereof, compositions comprising (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof, and methods for treating of or preventing relapse of depression, anxiety disorders, eating disorders, or urinary incontinence in a patient comprising administering (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof. The (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or pharmaceutically acceptable salt thereof is preferably substantially free of its corresponding (?)-enantiomer.

Abstract: The present invention relates to (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable salts thereof, compositions comprising (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof, and methods for treating of or preventing relapse of depression, anxiety disorders, eating disorders, or urinary incontinence in a patient comprising administering (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof. The (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or pharmaceutically acceptable salt thereof is preferably substantially free of its corresponding (−)-enantiomer.

Abstract: A method and apparatus for treating tinnitus involves generating a noise signal to mask the ringing or buzzing in the ears caused by tinnitus and transposing the noise signal into the ultrasonic frequency range. As such, the masking signal effectively masks the tinnitus noise without interfering with the subject's perception of normal sounds such as human speech. In an alternative embodiment, human speech is transduced into electrical signals, transposed to the ultrasonic frequency range, and physically applied to the patient while tinnitus masking signals in the auditory range are applied to the patient.

Abstract: Apparatus and method for shifting the frequency range of an audio frequency range signal using digital frequency shifting and single sideband amplitude modulation techniques. In one embodiment, a frequency shifted single sideband, amplitude modulated signal is formed for application to the human hearing sensory system to provide enhanced hearing for hearing impaired persons. In another embodiment, the audio signal is shifted to an ultrasonic frequency range utilizing digital signal processing techniques in which an audio frequency signal is frequency shifted by modulation to a carrier frequency and in which a single sideband modulated signal is formed. The digital single sideband amplitude modulation techniques of this embodiment are also applicable to digital modulation systems for uses other than in hearing aids. In another embodiment, analog single sideband modulation is utilized for frequency shifting in a hearing aid application.

Abstract: A hearing aid apparatus and method of the type in which audio frequency signals are frequency upshifted to ultrasonic frequency bands and are applied as vibrations to the human body to generate a hearing response. Frequency upshifting of the audio frequency signals to the ultrasonic frequency band is attained in one embodiment by amplitude modulation of an ultrasonic frequency carrier signal with an audio frequency modulating signal to form a modulated signal in which one of the two sidebands is either completely or substantially suppressed and a modulated signal having only one predominant sideband is thus derived for application to the human sensory system to generate a hearing response.

Abstract: An extended release formulation of diltiazem which is suitable for once-daily oral administration comprises a quantity of a quick release preparation of diltiazem or a pharmaceutically active salt thereof, mixed with a quantity of a slow release (or delayed release) preparation of diltiazem or a pharmaceutically active salt thereof. The quick release preparation used obtains a maximal release of diltiazem within approximately 1-2 hours after administration, and then falls toward baseline levels. The delayed release preparation individually shows a maximal release of diltiazem at between approximately 6-8 hours after administration.

Abstract: A virus having a lipid-containing capsid, such as AIDS virus, is inactivated by contacting the virus with an inactivating amount of phosphatidyl choline. Such a virus can be inactivated in fluids such as virus-contaminated body fluids or derivatives, e.g., blood or blood derivatives. The phosphatidyl choline can be present in an Active Lipid (AL) composition further comprising neutral lipids and phosphatidyl ethanolamine. Phosphatidyl choline, and an AL composition containing same, is useful for the treatment or prophylaxis of Acquired Immune Deficiency Syndrome (AIDS) in mammals.

Abstract: In a fluorescence immunoassay system, first and second fluorophores are covalently bound to one of a member of a specific binding pair of liquid and receptor, the first of said fluorophores being capable of absorbing light at a first wavelength to produce light emission at a second wavelength, which second wavelength can be absorbed by the second fluorophore.